Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276159 · ClinicalTrials.gov registry record · Phase 2
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00276159 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 6 participants.
The verdict
NCT00276159, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
Interventions
- DRUG 852A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276159
The ClinicalTrials.gov registry entry for NCT00276159 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 852A is the first listed.
NCT00276159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276159 about?
NCT00276159 is a clinical study titled "Study of Immune Response Modifier in the Treatment of Hematologic Malignancies". The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
What is the current status of trial NCT00276159?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2006-01. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00276159?
The interventions under investigation include: 852A (DRUG).
Who is sponsoring clinical trial NCT00276159?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.